EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 162 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $508,000 | -10.2% | 11,435 | 0.0% | 0.02% | +4.3% |
| Q1 2022 | $566,000 | -28.1% | 11,435 | -26.0% | 0.02% | -17.9% |
| Q4 2021 | $787,000 | -34.7% | 15,455 | -28.5% | 0.03% | -26.3% |
| Q3 2021 | $1,206,000 | +14.2% | 21,617 | -12.4% | 0.04% | +52.0% |
| Q2 2021 | $1,056,000 | +15.4% | 24,673 | +36.1% | 0.02% | +19.0% |
| Q1 2019 | $915,000 | +25.3% | 18,131 | 0.0% | 0.02% | +16.7% |
| Q4 2018 | $730,000 | +93.6% | 18,131 | +233.5% | 0.02% | +125.0% |
| Q3 2018 | $377,000 | -8.3% | 5,436 | 0.0% | 0.01% | -20.0% |
| Q2 2018 | $411,000 | +43.7% | 5,436 | 0.0% | 0.01% | +42.9% |
| Q1 2018 | $286,000 | -64.6% | 5,436 | -64.1% | 0.01% | -63.2% |
| Q4 2017 | $809,000 | +21.1% | 15,135 | +78.8% | 0.02% | +26.7% |
| Q2 2017 | $668,000 | +97.1% | 8,465 | +107.2% | 0.02% | +87.5% |
| Q1 2017 | $339,000 | +4.6% | 4,085 | 0.0% | 0.01% | +14.3% |
| Q4 2016 | $324,000 | – | 4,085 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |